You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 10,364,431


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,364,431
Title:Compositions for treating muscular dystrophy
Abstract: Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.
Inventor(s): Kaye; Edward M. (Cambridge, MA)
Assignee: Sarepta Therapeutics, Inc. (Cambridge, MA)
Application Number:15/604,335
Patent Claims: 1. A method for treating Duchenne muscular dystrophy (DMD) in a patient in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient a composition comprising eteplirsen, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein eteplirsen, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 30 mg/kg once a week for more than 120 weeks, such that disease progression in the patient is delayed, thereby treating the patient.

2. The method according to claim 1, wherein the patient is a pediatric patient.

3. The method of claim 2, wherein the patient is 7 years of age or older.

4. The method according to claim 1, wherein the patient is administered an oral corticosteroid for at least 24 weeks prior to the first dose of eteplirsen, or a pharmaceutically acceptable salt thereof.

5. The method according to claim 4, wherein the patient is a pediatric patient.

6. The method of claim 1, further comprising administering to the patient a corticosteroid.

7. The method of claim 6, wherein the corticosteroid is Betamethasone, Budesonide, Cortisone, Dexamethasone, Hydrocortisone, Methylprednisolone, Prednisolone, or Prednisone.

8. The method according to claim 6, wherein the patient is a pediatric patient.

9. The method of claim 6, wherein the corticosteroid is administered prior to, in conjunction with, or subsequent to administration of eteplirsen, or a pharmaceutically acceptable salt thereof.

10. The method of claim 1, wherein the composition further comprises a phosphate-buffered saline.

11. A method for restoring an mRNA reading frame to induce dystrophin production in a patient with Duchenne muscular dystrophy (DMD) in need thereof who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising intravenously administering to the patient a composition comprising eteplirsen, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein eteplirsen, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 30 mg/kg once a week for more than 120 weeks, such that disease progression in the patient is delayed.

12. The method according to claim 11, wherein the patient is a pediatric patient.

13. The method of claim 12, wherein the patient is 7 years of age or older.

14. The method according to claim 11, wherein the patient is administered an oral corticosteroid for at least 24 weeks prior to the first dose of eteplirsen, or a pharmaceutically acceptable salt thereof.

15. The method according to claim 14, wherein the patient is a pediatric patient.

16. The method of claim 11, further comprising administering to the patient a corticosteroid.

17. The method of claim 16, wherein the corticosteroid is Betamethasone, Budesonide, Cortisone, Dexamethasone, Hydrocortisone, Methylprednisolone, Prednisolone, or Prednisone.

18. The method according to claim 16, wherein the patient is a pediatric patient.

19. The method of claim 18, wherein the patient is 7 years of age or older.

20. The method of claim 17, wherein the corticosteroid is administered prior to, in conjunction with, or subsequent to administration of eteplirsen, or a pharmaceutically acceptable salt thereof.

21. The method of claim 11, wherein the pharmaceutically acceptable carrier is a pH buffered solution.

22. The method of claim 21, wherein the pH buffered solution is a phosphate-buffered saline.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.